PedAM
Pediatric Disease Annotations & Medicines
| Disease | proteinuria |
| Symptom | C0011881|diabetic nephropathy |
| Sentences | 42 |
| PubMedID- 23355027 | The present study aimed to identify the factors associated with nephrotic-range proteinuria in patients with advanced diabetic nephropathy. |
| PubMedID- 24273653 | There have been reports of mmp inhibitors, specifically doxycycline, successfully reducing proteinuria in patients with diabetic nephropathy (aggarwal et al. |
| PubMedID- 19605553 | The zucker fatty rats, a widely studied model of obesity and insulin resistance, exhibit glomerular hypertrophy, thickening of basement membranes and diffuse expansion of the glomerular mesangial matrix that resemble some of the histologic changes seen in diabetic nephropathy with proteinuria . |
| PubMedID- 20490905 | Like ace inhibitors and arbs, aliskiren, alone or in combination with an arb, has been shown to reduce proteinuria in patients with diabetic nephropathy. |
| PubMedID- 23434935 | Activation of protein kinase c (pkc) has been implicated in the pathogenesis of diabetic nephropathy with proteinuria and peritubular extracellular matrix production. |
| PubMedID- 22711280 | More importantly, our ckdp1 locus is syntenic to the human chromosome 3p14-12 and 3q21-22 regions, which have been linked to increased proteinuria in patients with type 1 diabetic nephropathy (osterholm et al, 2007; rogus et al, 1998). |
| PubMedID- 24455746 | Podocyte loss due to apoptosis and podocyte dysfunction contributes to proteinuria in patients with diabetic nephropathy . |
| PubMedID- 24159603 | Advanced diabetic nephropathy with nephrotic range proteinuria: a pilot study of the long-term efficacy of subcutaneous acth gel on proteinuria, progression of ckd, and urinary levels of vegf and mcp-1. |
| PubMedID- 20051769 | Effect of month-long treatment with oral n-acetylcysteine on the oxidative stress and proteinuria in patients with diabetic nephropathy: a pilot study. |
| PubMedID- 20138168 | Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. |
| PubMedID- 22218118 | Renoprotective effects of angiotensin receptor blockers and nac in preventing or reducing of proteinuria in patients with diabetic nephropathy was studied. |
| PubMedID- 25447989 | Based on these findings, dual raas blockade is no longer recommended for the routine treatment of various cardiovascular diseases, except diabetic nephropathy with proteinuria and hf with reduced ejection fraction. |
| PubMedID- 22973348 | The aim of this study was to evaluate the effect of pioglitazone on proteinuria among individuals with non-diabetic nephropathy. |
| PubMedID- 22759247 | In a recent study high dose cholecalciferol, showed a reduction in proteinuria in patients with diabetic nephropathy on ras blockade . |
| PubMedID- 22803087 | These patients were characterized by oxidative stress, diabetic nephropathy with associated proteinuria, and impairment of water excretion, electrolyte excretion, and nitrogen excretion in the kidneys. |
| PubMedID- 26068660 | Initial clinical trials show promise with regard to era effects on reducing proteinuria in patients with diabetic nephropathy (dn) who are already on renin-angiotensin system (ras) blocking agents. |
| PubMedID- 22954118 | Correlations of podocyte injury with glucose regulated protein 78 expression and proteinuria in patients with diabetic nephropathy. |
| PubMedID- 24779014 | Patients having microalbuminuria or proteinuria were diagnosed with diabetic nephropathy. |
| PubMedID- 23560927 | Yishen capsule includes an herb (astragalus membranaceus), which is known to treat proteinuria in patients with diabetic nephropathy. |
| PubMedID- 25621126 | In human diabetic nephropathy with proteinuria, sirt1 was downregulated and claudin1 was upregulated. |
| PubMedID- 26089878 | Effect of omega-3 fatty acid on the fatty acid content of the erythrocyte membrane and proteinuria in patients with diabetic nephropathy. |
| PubMedID- 21127830 | To be included, all cases in the report had to have diabetes mellitus with macroalbuminuria and/or overt proteinuria, esrd attributed to diabetic nephropathy or biopsy-proven diabetic nephropathy. |
| PubMedID- 26300986 | Therefore, we investigated whether pentoxifylline could reduce proteinuria in patients with diabetic nephropathy and residual proteinuria despite receiving an acei or arb. |
| PubMedID- 24327929 | Urinary nephrin mrna expression significantly correlated with the degree of proteinuria in patients with diabetic nephropathy, showing that nephrin mrna in the urine could possibly be clinically used as a biomarker to follow glomerulopathy progression in diabetic patients . |
| PubMedID- 24468233 | They also develop diabetic nephropathy with proteinuria and focal glomerulosclerosis that end in renal insufficiency 6. |
| PubMedID- 21864054 | The relationship between inflammation, endothelial dysfunction and proteinuria in patients with diabetic nephropathy. |
| PubMedID- 22126210 | Large clinical trials, such as the renaal study, have revealed that losartan exhibits renoprotective effects and inhibits overall mortality in type 2 diabetic nephropathy patients with overt proteinuria . |
| PubMedID- 24031106 | Pentoxifylline is a methylxanthine and possesses several properties that could have beneficial effects for patients with chronic obstructive pulmonary disease (copd) and pulmonary hypertension.1-4 with its anti-inflammatory, antifibrotic, and hemorheological properties,5 pentoxifylline has been demonstrated to increase the filterability of red blood cells (rbcs), decrease the adherence of rbcs to endothelial cells, blood viscosity, platelet aggregation, fibrinogen levels, and act as a vasodilator and improve pulmonary hemodynamics.6-11these effects can reduce the incidence of hypoxia by improving blood delivery to vascular beds.12 in animal models, the beneficial effects of pentoxifylline have been reported on hypoxia-induced skeletal muscle, lung, papillary muscle, and liver dysfunction.13-17 furthermore, it is an effective adjunct to compression bandaging for treating venous ulcers and may decrease proteinuria in patients with diabetic nephropathy.7 the food and drug administration (fda) has approved its use for the management of intermittent claudication.2 it is deserving of note that the majority of adverse effects of pentoxifylline are known to be gastrointestinal disturbances.18 there are, however, controversies over the beneficial effects of pentoxifylline in patients with copd with respect to improvement in the treadmill walk time, oxygen saturation, and dyspnea. |
| PubMedID- 22399858 | 33 in addition, some arbs may be more effective than others in reducing proteinuria in patients with diabetic nephropathy despite providing similar reductions in bp.34 nevertheless, the main renoprotective actions of arbs in general are largely mediated by their effects on bp.9 interestingly, the fda has not extended a general claim of nephroprotective benefits to all molecules in the arb class despite the fact that all approved arbs inhibit at1 signaling and lower bp. |
| PubMedID- 22707888 | Although a metaanalysis showed that pde inhibitor reduces proteinuria in patients with diabetic nephropathy, ptx has not been used in patients with diabetic nephropathy . |
| PubMedID- 25210405 | Some studies have reported beneficial effect of combination therapy on overt proteinuria in a patient with type 1 diabetic nephropathy1 and reduction in left ventricular hypertrophy in hypertensive patients. |
| PubMedID- 20682692 | Multiple clinical trials have shown that blockade of the renin-angiotensin system (ras) can improve renal function in late diabetic nephropathy in patients with proteinuria, diabetes, and reduced glomerular filtration rate (2–4). |
| PubMedID- 22555371 | Sulodexide has been shown to reduce proteinuria in patients with diabetic nephropathy6. |
| PubMedID- 25922592 | Available evidences indicate that ptx may decrease proteinuria in patients with diabetic nephropathy . |
| PubMedID- 26352002 | Previous studies have shown that aldosterone (ald) is involved in glomerular podocyte injury, and mineralocorticoid receptor (mr) blocker spironolactone effectively reduces proteinuria in patients with diabetic nephropathy. |
| PubMedID- 23866835 | 'huang qi elixir' for proteinuria in patients with diabetic nephropathy: a study protocol for a randomized controlled pilot trial. |
| PubMedID- 23843814 | diabetic nephropathy with proteinuria, including albuminurinuria, occurs in about 20 – 40 % of diabetics from which a considerable cases may proceed to severe renal failure (2, 3)and also to cardiovascular diseases (4-6). |
| PubMedID- 20203469 | Review of the amadeo study: reducing proteinuria in patients with diabetic nephropathy with telmisartan versus losartan. |
| PubMedID- 23199046 | The unique predictive value of plasma ccn2 in the progression of diabetic nephropathy, particularly in patients with severe proteinuria, suggests that ccn2 could also be used as a biomarker not only in diabetic patients who are likely to develop clinical nephropathy, but also in those who will exhibit rapid disease progression despite receiving appropriate treatment (table 1). |
| PubMedID- 26014479 | Increased circulatory and urinary levels of tnf-α have been found to be independently associated with increased proteinuria in patients with diabetic nephropathy. |
| PubMedID- 22529820 | Administration of spp301 on top of standard care including angiotensin-converting enzyme inhibitors (aceis) or high dose angiotensin receptor blockers (arbs) has been shown to result in a clinically relevant decrease in proteinuria in patients with diabetic nephropathy. |
| PubMedID- 25476525 | Methods: we performed a genome-wide association study using 1000 genomes-based imputation to compare type 1 diabetic nephropathy cases with proteinuria and with or without renal failure with control patients who have had diabetes for more than 15 years and no evidence of renal disease. |
Page: 1